Weight loss drug Belviq tied to ‘possible increased risk of cancer, ‘ FDA says

Weight loss drug Belviq tied to 'possible increased risk of cancer,' FDA says

Weight Loss Drug Belviq Tied To 'possible Increased Risk Of Cancer, ' FDA Says

Weight Loss Drug Belviq Tied To 'possible Increased Risk Of Cancer, ' FDA Says

( CNN) The US Food and Drug Administration warns that prescription weight loss medicine Belviq might be associated with an increased risk of cancer.

Weight Loss Drug Belviq Tied To 'possible Increased Risk Of Cancer, ' FDA Says
“At this time, the cause of the cancer is uncertain, and we cannot conclude that lorcaserin contributes to the cancer risk. However, we wanted to make the public aware of this potential risk. We are continuing to evaluate the clinical trial results and will communicate our final conclusions and recommendations when we have completed our review, ” the FDA said in its announcement.
The agency went on to note that health care professionals should consider if the benefits of taking lorcaserin exceeded the potential risks for a patient, and that patients currently taking the drug should talk to their doctors about the potential increased risk of cancer.

What is obesity?

Weight Loss Drug Belviq Tied To 'possible Increased Risk Of Cancer, ' FDA Says
Weight Loss Drug Belviq Tied To 'possible Increased Risk Of Cancer, ' FDA Says
Weight Loss Drug Belviq Tied To 'possible Increased Risk Of Cancer, ' FDA Says
Weight Loss Drug Belviq Tied To 'possible Increased Risk Of Cancer, ' FDA Says
Weight Loss Drug Belviq Tied To 'possible Increased Risk Of Cancer, ' FDA Says

Weight Loss Drug Belviq Tied To 'possible Increased Risk Of Cancer, ' FDA Says

Weight Loss Drug Belviq Tied To 'possible Increased Risk Of Cancer, ' FDA Says

Leave a Reply

Your email address will not be published. Required fields are marked *